美国炎症性肠病生物制剂治疗的市场份额与费用
基于Truven MarketScan数据库分析2007-2015年美国415405例炎症性肠病(IBD)患者的门诊用药趋势。生物制剂市场份额持续上升,克罗恩病(CD)使用比例从21.8%升至43.8%,溃疡性结肠炎(UC)从5.1%升至16.2%。生物制剂费用占比从2007年72.9%升至2015年85.7%。
要点
- 9年间生物制剂使用比例CD从21.8%升至43.8%,UC从5.1%升至16.2%。
- 生物制剂患者年均费用从2007年25275美元升至2015年36051美元。
- 生物制剂费用占比从2007年72.9%升至2015年85.7%。
核心结论
- 美国IBD门诊药物费用绝大部分归因于生物制剂使用的增加,尽管使用生物制剂的患者相对少数。
研究设计与样本
- 分析Truven MarketScan数据库2007-2015年克罗恩病和溃疡性结肠炎患者,共415405例(CD 188842例,UC 195183例,未定型结肠炎31380例,女性54.67%)。
主要发现
- CD患者使用生物制剂比例从21.8%升至43.8%,UC从5.1%升至16.2%。
- CD患者免疫调节剂和5-氨基水杨酸使用小幅下降,其他类别包括仅使用糖皮质激素作为主要IBD药物保持相对稳定。
- 生物制剂患者年均费用从2007年25275美元升至2015年36051美元。
- 儿童生物制剂患者年均费用从2007年23616美元升至2015年41109美元。
- 所有患者中生物制剂费用占比从2007年72.9%升至2015年85.7%,儿童从2007年81.7%升至2015年94.9%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Real-world data quantifying the costs of increasing use of biologics in inflammatory bowel disease (IBD) are unknown. AIM: To determine the outpatient IBD drug utilization trends, relative market share, and costs in the USA during a 9-year period. METHODS: The Truven MarketScan® Database was analysed for patients with Crohn's disease (CD) and ulcerative colitis (UC) during 2007-2015. National drug codes were used to identify prescription drugs; Healthcare Common Procedure Coding System J-codes were used to capture biologic out-patient infusions. Proportion of drug usage, relative market share and per-member per-year (PMPY) costs were analysed for biologics, immunomodulators, 5-ASAs and corticosteroids. RESULTS: In 415 405 patients (188 842 CD; 195 183 UC; 31 380 indeterminate colitis; 54.67% female), utilization trends show a consistent rise in the market share of biologics during the 9-year study period. The proportion of patients using biologics increased from 21.8% to 43.8% for CD and 5.1%-16.2% for UC. This contrasts a small decrease in immunomodulator and 5-ASA use for CD and relative constancy of other classes including corticosteroids-only use as primary IBD medication from 2007 to 2015. The average biologic-taking patient accounted for $25 275 PMPY in 2007 and $36 051 PMPY in 2015. The average paediatric biologic-taking patient accounted for $23 616 PMPY in 2007 and $41 109 PMPY in 2015. In all patients, the share of costs for biologics increased from 72.9% in 2007 to 85.7% in 2015 (81.7% in 2007 to 94.9% in 2015 in paediatrics). CONCLUSION: The vast majority of costs allocated to out-patient IBD medications in the USA is attributed to increasing use of biologic therapies despite the relative minority of biologic-taking patients.
引用
- Yu H, MacIsaac D, Wong JJ, et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment Pharmacol Ther. 2017. PMID: 29164650. doi:10.1111/apt.14430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。